Scribe Therapeutics wins $25m CIRM grant for preclinical CRISPR programs
What's the deal? US genetic medicines biotech Scribe Therapeutics has won more than $25 million from the California Institute for Regenerative MedicineDealroom has a profile for this one. Try Dealroom →.
The grant funds two preclinical cardiometabolic programs, STX-1200 and STX-1400, as they move toward clinical development.
Both are wholly-owned CRISPR-based gene editing therapies targeting cardiovascular and metabolic disease.
Why now? The awards came through the institute's Preclinical Development Program, which backs early-stage candidates before they reach human trials.
Scribe has spent years building its CRISPR platform, striking research deals with BiogenDealroom has a profile for this one. Try Dealroom → in 2020 and an Eli LillyDealroom has a profile for this one. Try Dealroom → unit in 2023.
What could go wrong? Preclinical programs face long odds. Both candidates must still clear safety and efficacy hurdles before any clinical trial begins.
Gene editing for cardiometabolic disease also remains largely unproven, adding scientific and regulatory risk.
The signal: Non-dilutive backing from a government and non-profit funder like the California Institute for Regenerative Medicine offers late-stage biotechs like Scribe a way to push preclinical programs forward without further diluting investors. With its CRISPR platform already validated through deals with Biogen and Eli Lilly, the grant marks another step in Scribe's bid to take next-generation gene editing from research into the clinic.
Read more: thepharmaletter.com
